Provided by Tiger Fintech (Singapore) Pte. Ltd.

Instil Bio, Inc.

15.09
+0.07000.47%
Post-market: 15.090.00000.00%16:10 EST
Volume:67.02K
Turnover:960.68K
Market Cap:101.87M
PE:-1.17
High:15.10
Open:14.80
Low:13.76
Close:15.02
52wk High:42.79
52wk Low:10.80
Shares:6.75M
Float Shares:3.31M
Volume Ratio:1.30
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9207
EPS(LYR):-11.3876
ROE:-51.74%
ROA:-12.86%
PB:0.77
PE(LYR):-1.33

Loading ...

Instil Bio Inc expected to post a loss of $2.35 a share - Earnings Preview

Reuters
·
Yesterday

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

GlobeNewswire
·
Nov 06

Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment

TIPRANKS
·
Oct 28

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

GlobeNewswire
·
Oct 24

TIL Limited Confirms Compliance with SEBI Regulations on Securities Dematerialization

TIPRANKS
·
Oct 13

Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?

Motley Fool
·
Oct 13

Citizens JMP healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 11

ImmuneOnco Biopharmaceuticals (Shanghai) Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China

Reuters
·
Oct 02

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
Sep 15

Instil Bio Price Target Maintained With a $125.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 11

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

GlobeNewswire
·
Sep 10

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Aug 29

Instil Bio Price Target Maintained With a $125.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 27

Instil Bio Price Target Maintained With a $125.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 15

Instil Bio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Instil Bio Q2 Adj. EPS $(2.88) Misses $(2.50) Estimate, Cash, Cash Equivalents, Restricted Cash, Marketable Securities And Long-term Investments Of $103.6M Will Enable The Company To Fund Its Operating Plan Beyond 2026

Benzinga
·
Aug 13

BRIEF-Instil Bio Q2 Basic EPS USD -3.24

Reuters
·
Aug 13

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 13

Instil Bio Inc expected to post a loss of $2.50 a share - Earnings Preview

Reuters
·
Aug 08

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

GlobeNewswire
·
Aug 08